BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 30082069)

  • 21. Design, synthesis, and biological evaluation of novel, highly active soft ROCK inhibitors.
    Boland S; Bourin A; Alen J; Geraets J; Schroeders P; Castermans K; Kindt N; Boumans N; Panitti L; Fransen S; Vanormelingen J; Stassen JM; Leysen D; Defert O
    J Med Chem; 2015 May; 58(10):4309-24. PubMed ID: 25898023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of 5H-chromeno[3,4-c]pyridine and 6H-isochromeno[3,4-c]pyridine derivatives as potent and selective dual ROCK inhibitors.
    Hu Z; Wang C; Sitkoff D; Cheadle NL; Xu S; Muckelbauer JK; Adam LP; Wexler RR; Quan ML
    Bioorg Med Chem Lett; 2020 Nov; 30(21):127474. PubMed ID: 32805407
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and evaluation of a series of 4-azaindole-containing p21-activated kinase-1 inhibitors.
    Lee W; Crawford JJ; Aliagas I; Murray LJ; Tay S; Wang W; Heise CE; Hoeflich KP; La H; Mathieu S; Mintzer R; Ramaswamy S; Rouge L; Rudolph J
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3518-24. PubMed ID: 27346791
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis and biological evaluation of 4-aryl-5-aminoalkyl-thiazole-2-amines derivatives as ROCK II inhibitors.
    Ma S; Wang L; Ouyang B; Fan M; Qi J; Yao L
    Bioorg Med Chem; 2020 Oct; 28(19):115683. PubMed ID: 32912437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chroman-3-amides as potent Rho kinase inhibitors.
    Chen YT; Bannister TD; Weiser A; Griffin E; Lin L; Ruiz C; Cameron MD; Schürer S; Duckett D; Schröter T; LoGrasso P; Feng Y
    Bioorg Med Chem Lett; 2008 Dec; 18(24):6406-9. PubMed ID: 18990570
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design of potent IGF1-R inhibitors related to bis-azaindoles.
    Nemecek C; Metz WA; Wentzler S; Ding FX; Venot C; Souaille C; Dagallier A; Maignan S; Guilloteau JP; Bernard F; Henry A; Grapinet S; Lesuisse D
    Chem Biol Drug Des; 2010 Aug; 76(2):100-6. PubMed ID: 20545947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of Novel N-Substituted Prolinamido Indazoles as Potent Rho Kinase Inhibitors and Vasorelaxation Agents.
    Yao Y; Li R; Liu X; Yang F; Yang Y; Li X; Shi X; Yuan T; Fang L; Du G; Jiao X; Xie P
    Molecules; 2017 Oct; 22(10):. PubMed ID: 29048389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 7-Azaindole: A Versatile Scaffold for Developing Kinase Inhibitors.
    Irie T; Sawa M
    Chem Pharm Bull (Tokyo); 2018; 66(1):29-36. PubMed ID: 29311509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors.
    Yin Y; Lin L; Ruiz C; Khan S; Cameron MD; Grant W; Pocas J; Eid N; Park H; Schröter T; Lograsso PV; Feng Y
    J Med Chem; 2013 May; 56(9):3568-81. PubMed ID: 23570561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. N-substituted azaindoles as potent inhibitors of Cdc7 kinase.
    Bryan MC; Falsey JR; Frohn M; Reichelt A; Yao G; Bartberger MD; Bailis JM; Zalameda L; Miguel TS; Doherty EM; Allen JG
    Bioorg Med Chem Lett; 2013 Apr; 23(7):2056-60. PubMed ID: 23481650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors.
    Daydé-Cazals B; Fauvel B; Singer M; Feneyrolles C; Bestgen B; Gassiot F; Spenlinhauer A; Warnault P; Van Hijfte N; Borjini N; Chevé G; Yasri A
    J Med Chem; 2016 Apr; 59(8):3886-905. PubMed ID: 27010810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In-Silico QSAR Modelling of Predicted Rho Kinase Inhibitors Against Cardio Vascular Diseases.
    Kesar S; Paliwal S; Sharma S; Mishra P; Chauhan M; Arya R; Madan K; Khan S
    Curr Comput Aided Drug Des; 2019; 15(5):421-432. PubMed ID: 30848208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and evaluation of C3 substituted chalcone-based derivatives of 7-azaindole as protein kinase inhibitors.
    Qhobosheane MA; Legoabe LJ; Josselin B; Bach S; Ruchaud S; Beteck RM
    Chem Biol Drug Des; 2020 Dec; 96(6):1395-1407. PubMed ID: 32558155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis, and biological evaluation of urea-based ROCK2 inhibitors.
    Wang L; Qi J; Fan M; Yao L
    Chem Biol Drug Des; 2021 Dec; 98(6):969-978. PubMed ID: 34581498
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimisation of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors.
    Ray P; Wright J; Adam J; Boucharens S; Black D; Brown AR; Epemolu O; Fletcher D; Huggett M; Jones P; Laats S; Lyons A; de Man J; Morphy R; Sherborne B; Sherry L; Straten Nv; Westwood P; York M
    Bioorg Med Chem Lett; 2011 Feb; 21(4):1084-8. PubMed ID: 21251828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel chemotype of kinase inhibitors: Discovery of 3,4-ring fused 7-azaindoles and deazapurines as potent JAK2 inhibitors.
    Wang T; Ledeboer MW; Duffy JP; Salituro FG; Pierce AC; Zuccola HJ; Block E; Shlyakter D; Hogan JK; Bennani YL
    Bioorg Med Chem Lett; 2010 Jan; 20(1):153-6. PubMed ID: 19945871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Triazine and pyrimidine based ROCK inhibitors with efficacy in spontaneous hypertensive rat model.
    Ho KK; Beasley JR; Belanger L; Black D; Chan JH; Dunn D; Hu B; Klon A; Kultgen SG; Ohlmeyer M; Parlato SM; Ray PC; Pham Q; Rong Y; Roughton AL; Walker TL; Wright J; Xu K; Xu Y; Zhang L; Webb M
    Bioorg Med Chem Lett; 2009 Nov; 19(21):6027-31. PubMed ID: 19800787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel ROCK inhibitors for the treatment of pulmonary arterial hypertension.
    Shaw D; Hollingworth G; Soldermann N; Sprague E; Schuler W; Vangrevelinghe E; Duggan N; Thomas M; Kosaka T; Waters N; van Eis MJ
    Bioorg Med Chem Lett; 2014 Oct; 24(20):4812-7. PubMed ID: 25248678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review on ROCK-II inhibitors: From molecular modelling to synthesis.
    Shah S; Savjani J
    Bioorg Med Chem Lett; 2016 May; 26(10):2383-2391. PubMed ID: 27080184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Rho kinase inhibitor azaindole-1 has long-acting vasodilator activity in the pulmonary vascular bed of the intact chest rat.
    Pankey EA; Byun RJ; Smith WB; Bhartiya M; Bueno FR; Badejo AM; Stasch JP; Murthy SN; Nossaman BD; Kadowitz PJ
    Can J Physiol Pharmacol; 2012 Jul; 90(7):825-35. PubMed ID: 22591047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.